Previous Close | 1.6200 |
Open | 1.6950 |
Bid | 1.6100 x 57900 |
Ask | 1.7200 x 150900 |
Day's Range | 1.6050 - 1.8000 |
52 Week Range | 1.3500 - 2.2700 |
Volume | |
Avg. Volume | 9,786 |
Market Cap | 42.739M |
Beta (5Y Monthly) | 0.79 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.1900 |
Earnings Date | Mar 27, 2024 - Apr 01, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 2.70 |
Subscribe to Yahoo Finance Plus to view Fair Value for MDG1.DE
Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will report financial results and provide a corporate update for the fiscal year ended December 31, 2023, on Thursday, March 28, 2024. Following the release of the full year 2023 earnings results and annual report on Medigene’s website, the Company will host a conference call that same day at 3 pm CET / 10 am
Planegg/Martinsried, March 6, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will present a poster at the American Association for Cancer Research Annual Meeting (AACR) 2024 taking place from April 5-10, 2024 in San Diego, USA as well as an oral presentation at the ELRIG-Forum 2024 to be held in Darmstadt, Germany on March 7, 2024. Poster presentati
Planegg/Martinsried, March 4, 2024. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today announced that the Company has been issued a patent by the Japan Patent Office protecting its inducible Medigene T cell receptor (iM-TCR), a control mechanism to regulate efficacy and safety of its T cell receptor engineered T cell (TCR-T) therapies. “We are delighted with the receipt